Pretreatment characteristics of patients
| Clinical feature . | Sequential arm (n = 53) . | Concurrent arm (n = 51) . |
|---|---|---|
| Median age, y (range) | 63 (36-79) | 63 (36-86) |
| Stage | ||
| No. (%) Rai intermediate risk | 31 (58) | 31 (61) |
| No. (%) Rai high risk | 22 (42) | 20 (39) |
| Females, % | 19 | 27 |
| CALGB performance status | ||
| 0, % | 53 | 61 |
| 1, % | 42 | 31 |
| 2, % | 4 | 4 |
| 3, % | 2 | 0 |
| B2M, % | ||
| 0-3 mg/L | 26 | 37 |
| 3.1-5 mg/L | 34 | 24 |
| Greater than 5 mg/L | 13 | 16 |
| Missing | 26 | 24 |
| Median (range) leukocyte count, × 109/L | 80 (8.8-366) | 85 (12.3-436) |
| Median (range) hemoglobin, g/dL | 12.6 (6.3-15.2) | 12.9 (6.3-16.1) |
| Hemoglobin, % | ||
| At least 11 g/dL | 82 | 82 |
| Less than 11 g/dL | 18 | 18 |
| Median (range) platelets, × 1012/L | 131 (34-306) | 153 (33-316) |
| Splenomegaly, % | 61 | 60 |
| Hepatomegaly, % | 16 | 15 |
| Adenopathy, % | 94 | 94 |
| Clinical feature . | Sequential arm (n = 53) . | Concurrent arm (n = 51) . |
|---|---|---|
| Median age, y (range) | 63 (36-79) | 63 (36-86) |
| Stage | ||
| No. (%) Rai intermediate risk | 31 (58) | 31 (61) |
| No. (%) Rai high risk | 22 (42) | 20 (39) |
| Females, % | 19 | 27 |
| CALGB performance status | ||
| 0, % | 53 | 61 |
| 1, % | 42 | 31 |
| 2, % | 4 | 4 |
| 3, % | 2 | 0 |
| B2M, % | ||
| 0-3 mg/L | 26 | 37 |
| 3.1-5 mg/L | 34 | 24 |
| Greater than 5 mg/L | 13 | 16 |
| Missing | 26 | 24 |
| Median (range) leukocyte count, × 109/L | 80 (8.8-366) | 85 (12.3-436) |
| Median (range) hemoglobin, g/dL | 12.6 (6.3-15.2) | 12.9 (6.3-16.1) |
| Hemoglobin, % | ||
| At least 11 g/dL | 82 | 82 |
| Less than 11 g/dL | 18 | 18 |
| Median (range) platelets, × 1012/L | 131 (34-306) | 153 (33-316) |
| Splenomegaly, % | 61 | 60 |
| Hepatomegaly, % | 16 | 15 |
| Adenopathy, % | 94 | 94 |